Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy
Аутори
Bačković, DraganaNovković, Mirjana
Matić, Dragan
Antonijević, Nebojša
Strugarević, Evgenija
Kovač, Mirjana
Kušić-Tišma, Jelena
Rakićević, Ljiljana
Radojković, Dragica
Остала ауторства
Obradović, SlobodanКонференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Introduction. Despite proven clinical effect of clopidogrel, a
considerable number of patients do not have an adequate
response to this type of medication. Problems during therapy occur in the form of resistance, which is present in 11%
of patients or bleeding that occurs in about 9% of patients.
Pharmacogenomics studies demonstrated that variants of
the CYP2C19 gene significantly influence the interindividual heterogenity of the clopidogrel response. The American
Heart Association, US Food and Drug Administration and the
European Medicines Agency, cite the CYP2C19 gene as a significant factor which influences patients response to clopidogrel. Further, it has been shown that the contribution of
genetic and non-genetic factors affecting clopidogrel therapy
may vary between patients from different populations, which
justifies conducting population-specific studies.
The aim. The aim of our study was to examine the significance
of the CYP2C19*2 and the CYP2C19*17 variants in th...e individual response to clopidogrel, in Serbian patients.
Methods. The study involved 108 patients with carotid artery
stenosis who underwent endarterectomy and received clopidogrel for at least 30 days after the intervention. Also, 120
patients with myocardial infarction receiving clopidogrel after PCI (percutaneous coronary intervention) were included.
Commercial tests were used for standard laboratory testing.
Allelic discrimination was performed after Sanger sequencing.
Results were analysed using statistical tests.
Results. In patients undergoing endarterectomy CYP2C19*2
carriers had a higher risk for being clopidogrel low-responder
in comparison with non-carriers (1.250, 95% CI 1.695–1.658,
P<0.01). In the group of patients undergoing PCI, risk for reinfarction in patients who were carriers of CYP2C19*2 was higher
compared to patients with wild type genotype (OR 5.355, 95%
CI 0.955-31.08; P=0.038). Variant CYP2C19*17 showed no association with variations in response to clopidogrel therapy.
Conclusion. The CYP2C19*2 variant shows significant association with a poor response to clopidogrel and it should be
considered when planning therapy.
Извор:
Heart and Blood Vessels, 2021, 40, 3Издавач:
- Beograd : Udruženje kardiologa Srbije
Напомена:
- XXIII Congress of the Cardiology society of Serbia, October 21-23, 2021, Belgrade, Serbia.
URI
https://www.uksrb.rs/en/magazine/archive/heart-and-blood-vessels-number-32021https://imagine.imgge.bg.ac.rs/handle/123456789/2344
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Bačković, Dragana AU - Novković, Mirjana AU - Matić, Dragan AU - Antonijević, Nebojša AU - Strugarević, Evgenija AU - Kovač, Mirjana AU - Kušić-Tišma, Jelena AU - Rakićević, Ljiljana AU - Radojković, Dragica PY - 2021 UR - https://www.uksrb.rs/en/magazine/archive/heart-and-blood-vessels-number-32021 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2344 AB - Introduction. Despite proven clinical effect of clopidogrel, a considerable number of patients do not have an adequate response to this type of medication. Problems during therapy occur in the form of resistance, which is present in 11% of patients or bleeding that occurs in about 9% of patients. Pharmacogenomics studies demonstrated that variants of the CYP2C19 gene significantly influence the interindividual heterogenity of the clopidogrel response. The American Heart Association, US Food and Drug Administration and the European Medicines Agency, cite the CYP2C19 gene as a significant factor which influences patients response to clopidogrel. Further, it has been shown that the contribution of genetic and non-genetic factors affecting clopidogrel therapy may vary between patients from different populations, which justifies conducting population-specific studies. The aim. The aim of our study was to examine the significance of the CYP2C19*2 and the CYP2C19*17 variants in the individual response to clopidogrel, in Serbian patients. Methods. The study involved 108 patients with carotid artery stenosis who underwent endarterectomy and received clopidogrel for at least 30 days after the intervention. Also, 120 patients with myocardial infarction receiving clopidogrel after PCI (percutaneous coronary intervention) were included. Commercial tests were used for standard laboratory testing. Allelic discrimination was performed after Sanger sequencing. Results were analysed using statistical tests. Results. In patients undergoing endarterectomy CYP2C19*2 carriers had a higher risk for being clopidogrel low-responder in comparison with non-carriers (1.250, 95% CI 1.695–1.658, P<0.01). In the group of patients undergoing PCI, risk for reinfarction in patients who were carriers of CYP2C19*2 was higher compared to patients with wild type genotype (OR 5.355, 95% CI 0.955-31.08; P=0.038). Variant CYP2C19*17 showed no association with variations in response to clopidogrel therapy. Conclusion. The CYP2C19*2 variant shows significant association with a poor response to clopidogrel and it should be considered when planning therapy. PB - Beograd : Udruženje kardiologa Srbije C3 - Heart and Blood Vessels T1 - Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy IS - 3 VL - 40 UR - https://hdl.handle.net/21.15107/rcub_imagine_2344 ER -
@conference{ author = "Bačković, Dragana and Novković, Mirjana and Matić, Dragan and Antonijević, Nebojša and Strugarević, Evgenija and Kovač, Mirjana and Kušić-Tišma, Jelena and Rakićević, Ljiljana and Radojković, Dragica", year = "2021", abstract = "Introduction. Despite proven clinical effect of clopidogrel, a considerable number of patients do not have an adequate response to this type of medication. Problems during therapy occur in the form of resistance, which is present in 11% of patients or bleeding that occurs in about 9% of patients. Pharmacogenomics studies demonstrated that variants of the CYP2C19 gene significantly influence the interindividual heterogenity of the clopidogrel response. The American Heart Association, US Food and Drug Administration and the European Medicines Agency, cite the CYP2C19 gene as a significant factor which influences patients response to clopidogrel. Further, it has been shown that the contribution of genetic and non-genetic factors affecting clopidogrel therapy may vary between patients from different populations, which justifies conducting population-specific studies. The aim. The aim of our study was to examine the significance of the CYP2C19*2 and the CYP2C19*17 variants in the individual response to clopidogrel, in Serbian patients. Methods. The study involved 108 patients with carotid artery stenosis who underwent endarterectomy and received clopidogrel for at least 30 days after the intervention. Also, 120 patients with myocardial infarction receiving clopidogrel after PCI (percutaneous coronary intervention) were included. Commercial tests were used for standard laboratory testing. Allelic discrimination was performed after Sanger sequencing. Results were analysed using statistical tests. Results. In patients undergoing endarterectomy CYP2C19*2 carriers had a higher risk for being clopidogrel low-responder in comparison with non-carriers (1.250, 95% CI 1.695–1.658, P<0.01). In the group of patients undergoing PCI, risk for reinfarction in patients who were carriers of CYP2C19*2 was higher compared to patients with wild type genotype (OR 5.355, 95% CI 0.955-31.08; P=0.038). Variant CYP2C19*17 showed no association with variations in response to clopidogrel therapy. Conclusion. The CYP2C19*2 variant shows significant association with a poor response to clopidogrel and it should be considered when planning therapy.", publisher = "Beograd : Udruženje kardiologa Srbije", journal = "Heart and Blood Vessels", title = "Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy", number = "3", volume = "40", url = "https://hdl.handle.net/21.15107/rcub_imagine_2344" }
Bačković, D., Novković, M., Matić, D., Antonijević, N., Strugarević, E., Kovač, M., Kušić-Tišma, J., Rakićević, L.,& Radojković, D.. (2021). Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy. in Heart and Blood Vessels Beograd : Udruženje kardiologa Srbije., 40(3). https://hdl.handle.net/21.15107/rcub_imagine_2344
Bačković D, Novković M, Matić D, Antonijević N, Strugarević E, Kovač M, Kušić-Tišma J, Rakićević L, Radojković D. Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy. in Heart and Blood Vessels. 2021;40(3). https://hdl.handle.net/21.15107/rcub_imagine_2344 .
Bačković, Dragana, Novković, Mirjana, Matić, Dragan, Antonijević, Nebojša, Strugarević, Evgenija, Kovač, Mirjana, Kušić-Tišma, Jelena, Rakićević, Ljiljana, Radojković, Dragica, "Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy" in Heart and Blood Vessels, 40, no. 3 (2021), https://hdl.handle.net/21.15107/rcub_imagine_2344 .